0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-2 R beta

IL-2 R beta

Brief Information

Name:Interleukin-2 receptor alpha chain
Target Synonym:TAC antigen,p55,IL2-RA,Interleukin-2 receptor subunit alpha,IL-2-RA,IL-2R subunit alpha,IL2RA,Interleukin 2 Receptor Subunit Alpha,Interleukin 2 Receptor, Alpha,IL-2 Receptor Subunit Alpha,CD25 Antigen,IDDM10,IMD41,TCGFR,CD25,IL2R,Insulin-Dependent Diabet
Number of Launched Drugs:4
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

CD2-H5221-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Human IL-2 R beta, His Tag (SPR verified) (Cat. No. CD2-H5221) inhibits the IL-15-dependent proliferation of Mo7e cells. The EC50 for this effect is 0.38-0.45 µg/mL (Routinely tested).

ILB-H5253-SPR
Human_FcRn_Heterodimer_Protein_SPR

Human IL-2 R beta, Fc Tag (Cat. No. ILB-H5253) captured on CM5 chip via anti-human IgG Fc antibody can bind IL-2, Tag Free (Cat. No. IL2-H4113) with an affinity constant of 0.473 μM as determined in a SPR assay (Biacore T200) (QC tested).

CD2-H5221-SPR
Human_FcRn_Heterodimer_Protein_SPR

Human IL-2 R beta, His Tag (SPR verified) (Cat. No. CD2-H5221) captured on CM5 chip via anti-His antibody, can bind Human IL-2, Tag Free (Cat. No. IL2-H4113) with an affinity constant of 0.525 μM as determined in a SPR assay (Biacore T200) (QC tested).

Synonym Name

IL2RB,RP5-1170K4.6,CD122,P70-75

Background

Interleukin-2 receptor (IL-2R) is a heterotrimeric protein expressed on the surface of certain immune cells, such as lymphocytes, that binds and responds to a cytokine called IL-2. The IL-2R is made up of 3 subunits - α (CD25), β (CD122) and γ (CD132) - non-covalently associating. The α and β chains are involved in binding IL-2, while signal transduction following cytokine interaction is carried out by the γ-chain, along with the β subunit. CD122 is also known as IL2R beta, is a member of the type I cytokine receptor family. CD122 is the receptor for interleukin-2 and is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2.

Clinical and Translational Updates

Related Molecule

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Basiliximab CHT-25; chRFT5; CHI-621; SDZ-CHI-621 Approved Novartis Pharma Ag 舒莱, Simulect Japan Rejection of organ transplantation Novartis Pharma Ag 1998-05-12 Rejection of renal transplantation; Rejection of organ transplantation; Colitis, Ulcerative; Uveitis Details
Recombinant Human Interleukin-2(Ⅰ) (Liaoning Satellite Biological Products) Approved Liaoning Satellite Biological Products Research Institute (Limited) Mainland China Neoplasms Liaoning Satellite Biological Products Research Institute (Limited) 2002-02-04 Neoplasms Details
Daclizumab R-35; BIIB-019; RO-247375 Approved Abbvie Inc, Biogen Inc, F. Hoffmann-La Roche Ltd Zinbryta, Zenapax United States Multiple Sclerosis Biogen Inc 1997-12-10 Multiple Sclerosis, Relapsing-Remitting; Gastrointestinal Diseases; Inflammatory Bowel Diseases; Multiple Sclerosis; Rejection of organ transplantation; Asthma; Colitis, Ulcerative Details
Denileukin diftitox E-7272; E-7777; DAB-389; LY-335348; DAB389IL-2 Approved Eisai Co Ltd Ontak, Onzar United States Lymphoma, T-Cell, Cutaneous Eisai Inc 1999-02-05 Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell; Leukemia; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma Details
Daclizumab biosimilar (Shanghai CP Guojian) Approved Shanghai Cp Guojian Pharmaceutical Co Ltd 健尼哌 Mainland China Rejection of renal transplantation null 2011-01-12 Rejection of renal transplantation Details
Basiliximab CHT-25; chRFT5; CHI-621; SDZ-CHI-621 Approved Novartis Pharma Ag 舒莱, Simulect Japan Rejection of organ transplantation Novartis Pharma Ag 1998-05-12 Rejection of renal transplantation; Rejection of organ transplantation; Colitis, Ulcerative; Uveitis Details
Recombinant Human Interleukin-2(Ⅰ) (Liaoning Satellite Biological Products) Approved Liaoning Satellite Biological Products Research Institute (Limited) Mainland China Neoplasms Liaoning Satellite Biological Products Research Institute (Limited) 2002-02-04 Neoplasms Details
Daclizumab R-35; BIIB-019; RO-247375 Approved Abbvie Inc, Biogen Inc, F. Hoffmann-La Roche Ltd Zinbryta, Zenapax United States Multiple Sclerosis Biogen Inc 1997-12-10 Multiple Sclerosis, Relapsing-Remitting; Gastrointestinal Diseases; Inflammatory Bowel Diseases; Multiple Sclerosis; Rejection of organ transplantation; Asthma; Colitis, Ulcerative Details
Denileukin diftitox E-7272; E-7777; DAB-389; LY-335348; DAB389IL-2 Approved Eisai Co Ltd Ontak, Onzar United States Lymphoma, T-Cell, Cutaneous Eisai Inc 1999-02-05 Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell; Leukemia; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma Details
Daclizumab biosimilar (Shanghai CP Guojian) Approved Shanghai Cp Guojian Pharmaceutical Co Ltd 健尼哌 Mainland China Rejection of renal transplantation null 2011-01-12 Rejection of renal transplantation Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Inolimomab B-B10; BT-563; MAb-BT-563 Phase 3 Clinical Eusa Pharma, Jazz Pharmaceuticals Graft vs Host Disease Details
Anti-interleukin-2 receptor monoclonal antibody Mikbeta1 HuMikβ1-1 Phase 1 Clinical F. Hoffmann-La Roche Ltd, National Institutes Of Health Leukemia, Lymphoid Details
Basiliximab biobetter (Mabtech/Sorrento) STI-003 Phase 3 Clinical Taizhou Maibo Taike Biotechnology Co Ltd Autoimmune Diseases Details
ANV-419 Phase 2 Clinical Anaveon AG Solid tumours Details
Camidanlumab tesirine ADCT-301 Phase 2 Clinical Genmab, Adc Therapeutics Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Lymphoma, Non-Hodgkin; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Colorectal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Urinary Bladder Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Hodgkin Disease; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms Details
Inolimomab B-B10; BT-563; MAb-BT-563 Phase 3 Clinical Eusa Pharma, Jazz Pharmaceuticals Graft vs Host Disease Details
Anti-interleukin-2 receptor monoclonal antibody Mikbeta1 HuMikβ1-1 Phase 1 Clinical F. Hoffmann-La Roche Ltd, National Institutes Of Health Leukemia, Lymphoid Details
Basiliximab biobetter (Mabtech/Sorrento) STI-003 Phase 3 Clinical Taizhou Maibo Taike Biotechnology Co Ltd Autoimmune Diseases Details
ANV-419 Phase 2 Clinical Anaveon AG Solid tumours Details
Camidanlumab tesirine ADCT-301 Phase 2 Clinical Genmab, Adc Therapeutics Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Lymphoma, Non-Hodgkin; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Colorectal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Urinary Bladder Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Hodgkin Disease; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms Details

This web search service is supported by Google Inc.

totop